	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	176.51	166.46	143.85	138.15	144.08	143.87	126.53	166.83	158.57	187.95	217.58	236.71	208.70	268.72	287.23	293.85
Cost of Operating Revenue	89.89	92.20	70.19	71.39	62.22	60.94	61.43	73.86	57.32	81.86	91.28	94.73	81.97	104.99	113.82	115.31
Gross Profit	86.62	74.27	73.66	66.76	81.86	82.93	65.10	92.96	101.25	106.08	126.31	141.98	126.73	163.72	173.41	178.54
Gross Margin	49.1	44.6	51.2	48.3	56.8	57.6	51.5	55.7	63.9	56.4	58.0	60.0	60.7	60.9	60.4	60.8
Total Operating Expenses	162.44	159.12	136.00	132.13	134.77	140.10	137.96	158.51	151.17	169.95	193.08	203.05	187.24	225.78	238.59	241.98
Operating Profit	14.08	7.35	7.85	6.02	9.31	3.77	-11.43	8.32	7.40	17.99	24.50	33.66	21.46	42.94	48.63	51.87
Operating Margin	8.0	4.4	5.5	4.4	6.5	2.6	-9.0	5.0	4.7	9.6	11.3	14.2	10.3	16.0	16.9	17.7
Financing Income/(Expense) - Net	-4.31	-5.10	-5.32	-4.46	-5.30	-2.64	-0.66	-0.75	-0.51	-0.51	2.40	3.61	7.78	6.62	-1.03	-1.02
Profit before Taxes	10.09	2.54	2.53	1.67	4.08	14.40	-11.63	9.00	9.41	21.87	26.64	34.81	29.87	69.86	57.52	60.77
Income Taxes	2.63	0.70	0.41	0.50	0.82	2.53	-0.08	1.79	1.54	4.81	7.79	8.09	7.41	14.50	14.44	15.29
Profit after Tax	7.46	1.83	2.12	1.17	3.25	11.86	-11.55	7.22	7.87	17.06	18.86	26.72	22.46	55.36	43.08	45.48
PAT Margin	4.2	1.1	1.5	0.8	2.3	8.2	-9.1	4.3	5.0	9.1	8.7	11.3	10.8	20.6	15.0	15.5
EPS - Basic - ex Extraordinary Items	1.14	0.28	0.32	0.18	0.50	1.81	-1.76	1.10	1.20	2.60	2.88	4.08	3.40	8.26	6.40	6.80
EPS - Diluted - ex Extraordinary Items	1.14	0.28	0.32	0.18	0.50	1.81	-1.76	1.10	1.20	2.60	2.88	4.08	3.39	8.22	6.31	6.71
EBIT	14.08	7.35	7.85	6.02	9.31	3.77	-11.43	8.32	7.40	17.99	24.50	33.66	21.46	42.94	48.63	51.87
EBITDA	16.99	10.46	10.68	8.73	12.40	5.77	-10.36	9.34	8.53	19.08	26.03	34.84	23.13	51.07	58.07	61.10
EBITDA Margin	9.6	6.3	7.4	6.3	8.6	4.0	-8.2	5.6	5.4	10.2	12.0	14.7	11.1	19.0	20.2	20.8

Balance Sheet

Abridged

Understanding Balance Sheet

Jagsonpal Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	R 2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	R 2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	IR	AR	AR	AR	AR	AR	AR	IR	AR	AR	AR	AR	PRESS
Total Current Assets	90.93	86.54	91.31	95.79	100.96	110.11	94.61	97.56	96.31	118.63	109.08	164.56	199.25	161.19	143.09
Long-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.39	21.60	29.05	3.76	5.17	17.39	85.11
Property Plant & Equipment - Net	60.05	60.65	58.73	51.93	51.58	21.56	22.27	23.51	23.96	23.35	22.57	24.28	9.30	8.84	7.35
Total Non-Current Assets	65.17	66.46	64.94	58.43	58.32	32.50	35.20	38.23	52.39	46.19	55.14	30.39	17.82	117.07	173.59
Total Assets	156.10	153.00	156.26	154.22	159.28	142.61	129.81	135.78	148.69	164.81	164.22	194.95	217.08	278.26	316.68
Total Current Liabilities	53.38	50.13	53.58	55.19	57.31	29.44	28.58	28.19	34.57	37.03	26.97	27.57	19.13	25.90	28.30
Long Term Debt	0.27	0.32	-	-	-	-	-	-	-	-	-	5.25	7.56	7.63	6.59
Total Non-Current Liabilities	4.25	4.50	4.08	3.60	3.61	3.26	3.19	3.12	3.09	2.02	4.49	8.48	10.55	12.41	12.21
Total Liabilities	57.63	54.63	57.67	58.79	60.92	32.70	31.77	31.31	37.66	39.04	31.47	36.06	29.68	38.31	40.51
Total Shareholders' Equity	98.47	98.37	98.59	95.43	98.36	109.91	98.05	104.47	111.03	125.77	132.76	158.89	187.40	239.95	276.17
Total Equity	98.47	98.37	98.59	95.43	98.36	109.91	98.05	104.47	111.03	125.77	132.76	158.89	187.40	239.95	276.17
Total Liabilities & Equity	156.10	153.00	156.26	154.22	159.28	142.61	129.81	135.78	148.69	164.81	164.22	194.95	217.08	278.26	316.68

Cash Flow

Abridged

Understanding Cash Flow Statement

Jagsonpal Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	R 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	10.24	4.41	4.79	3.93	5.70	0.24	-11.02	10.44	8.70	18.49	19.63	40.07	36.18	56.66	58.74
Working Capital - Increase/(Decrease)	-7.51	2.50	-2.65	-4.09	-1.96	-6.13	8.79	19.71	4.84	11.59	-11.46	9.88	5.54	5.52	-2.39
Net CF from Operating Activities	2.72	6.92	2.14	-0.16	3.74	-5.89	-2.23	30.15	13.54	30.09	8.18	49.95	41.72	62.18	56.35
Capital Expenditures - Net	5.31	3.72	1.28	0.58	2.75	-40.82	3.83	2.25	1.85	0.47	0.47	-0.98	0.25	-35.37	0.15
Net CF from Investing Activities	-4.94	-3.39	-1.21	-0.46	-2.09	41.29	-3.37	-0.83	-13.24	-4.64	-27.32	-61.10	-31.91	-52.99	-46.09
Dividends Paid - Cash - Total	1.31	1.31	1.31	0.26	0.26	0.26	0.26	0.66	1.31	2.62	10.48	-	13.10	13.23	16.66
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	-	-	-3.69	-	-	5.63	3.39	6.63
Debt - LT & ST - Issuance/(Retirement) - Total	6.29	-1.54	2.87	3.35	-0.82	-30.56	0.37	-4.52	-	-	-6.79	-0.32	-0.63	-0.90	-1.22
Net Cash Flow from Financing Activities	4.77	-3.06	1.34	3.04	-1.13	-30.88	0.06	-5.30	-1.31	-6.31	-17.27	-0.32	-8.10	-10.74	-11.25
Free Cash Flow to Equity	3.71	1.66	3.73	2.62	0.17	4.37	-5.69	23.38	11.68	29.62	0.92	50.60	40.84	96.65	54.98
Free Operating CF net dividend	-3.89	1.89	-0.45	-1.00	0.73	-8.73	-6.32	27.24	10.37	27.00	-3.35	49.63	28.37	48.61	39.54
Free Operating CF	-2.58	3.20	0.86	-0.74	0.99	-8.47	-6.06	27.90	11.68	29.62	7.13	49.63	41.47	61.83	56.20

Business Segment Analysis

FY End:

Mar 25

Jagsonpal Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutical business (100.0%)₹ 0.35 Cr

Revenue / Sales

Pharmaceutical business (100.0%)₹ 268.72 Cr

Assets

Pharmaceutical business (100.0%)₹ 278.26 Cr

Operating Income

Pharmaceutical business (100.0%)₹ 42.94 Cr

Regional Segment Analysis

FY End:

Mar 25

Jagsonpal Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (100.0%)₹ 268.72 Cr

Assets

India (100.0%)₹ 278.26 Cr

Historical Segment Analysis

Track how Jagsonpal Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
Pharmaceutical business	0	0	0	0

Frequently Asked Questions

What is the revenue of Jagsonpal Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Jagsonpal Pharmaceuticals Ltd. is ₹ 293.85 Cr, reflecting a 1-year growth of 3.87% and a 3-year CAGR of 7.54%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Jagsonpal Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Jagsonpal Pharmaceuticals Ltd. is ₹ 45.48 Cr, with a 3-year earnings CAGR of 12.03%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Jagsonpal Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Jagsonpal Pharmaceuticals Ltd. is approximately ₹ 51.87 Cr (based on an operating margin of 17.65%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Jagsonpal Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Jagsonpal Pharmaceuticals Ltd. is 6.71. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Jagsonpal Pharmaceuticals Ltd.?

The debt-to-equity ratio of Jagsonpal Pharmaceuticals Ltd. stands at 0.03. The interest coverage ratio is 50.60x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Jagsonpal Pharmaceuticals Ltd.?

The estimated book value per share of Jagsonpal Pharmaceuticals Ltd. is 41.87 (derived from a P/B ratio of 5.79 and market price of ₹ 242.50), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Jagsonpal Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Jagsonpal Pharmaceuticals Ltd. is ₹ 56.35 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Jagsonpal Pharmaceuticals Ltd. report consolidated or standalone financials?

Jagsonpal Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.